Eloxx Pharmaceuticals Inc (ELOX) Return on Equity ROE from the first quarter 2026 to first quarter 2023 and annually, average high and low, overall ranking from Mar 31 2026 to Mar 31 2023 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Eloxx Pharmaceuticals Inc   (NASDAQ: ELOX)

Eloxx Pharmaceuticals Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Eloxx Pharmaceuticals Inc in the first quarter 2026?
Due to the lack of equity, it was not possible to calculate Eloxx Pharmaceuticals Inc 's return on equity (ROE) in its first quarter 2026

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2023)
III. Quarter		 (Jun 30 2023)
II. Quarter		 (Mar 31 2023)
I. Quarter
Y / Y Equity Change - - - - -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -4 -6 -20 -24 -31
Return On Equity (TTM) - - - - -4981.73 %
ELOX's Total Ranking # # # # #
Equity (TTM) in Millions -8 -12 -20 -19 16
Seq. Equity Change - - - - -
Seq. Net Income Change - - - - -

Back to ELOX Management Effectiveness >> ELOX's 5 Years Annual ROE >> Compare ELOX ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry #
Sector #
Overall #

Return On Equity Statistics
High Average Low
0 %
0 %
0 %
 





ELOX Annual Return On Equity (Dec 31 2025)
2025		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021		 (Dec 31 2020)
2020		 (Dec 31 2019)
2019
Total Equity in Millions -12 -11 22 10 36
Y / Y Equity Change - - 118.81 % -71.75 % -15.61 %
Net Income in Millions -6 -36 -67 -35 -51
Y / Y Net Income Change - - - - -
Return On Equity - - -298.1 % -338 % -140.49 %

Back to ELOX Management Effectiveness >> ELOX's 5 Years Annual ROE >> Compare ELOX ROE to its Competitors




More Return On Equity Ratios
Biotechnology & Pharmaceuticals Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
ELOX's' Return on Equity at Yahoo Finance
ELOX's Roe Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for ELOX's Competitors
Subscribers only: Roe for Eloxx Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Equity for ELOX's Customers




Companies with similar Return On Equity at Mar 31 2026, within Healthcare Sector ROE
3m Company  65.54 %
Aurinia Pharmaceuticals Inc   64.48 %
Lifemd Inc   63.70 %
Zoetis Inc   61.63 %
Vaxart Inc   61.43 %
Dariohealth Corp   60.52 %
Nrc Health  57.25 %
Oramed Pharmaceuticals Inc  55.40 %
Innoviva Inc   47.59 %
Concentra Group Holdings Parent Inc   46.95 %
Liquidia Corporation  46.82 %
Agilent Technologies inc   44.45 %
Tenet Healthcare Corp  44.20 %
Theravance Biopharma inc   43.85 %
Gilead Sciences Inc   42.33 %
Transmedics Group Inc   41.92 %
Abeona Therapeutics Inc   41.40 %
Apellis Pharmaceuticals Inc   39.71 %
Adma Biologics Inc   38.97 %
Bristol myers Squibb Company  38.94 %
Acadia Pharmaceuticals Inc   35.65 %
Spero Therapeutics Inc   35.58 %
Illumina Inc   33.99 %
Dexcom Inc   33.83 %
Rafael Holdings Inc  31.93 %
Solventum Corporation  30.71 %
Phibro Animal Health Corporation  30.60 %
Pro dex Inc   30.01 %
Incyte Corporation  29.20 %
Protalix Biotherapeutics inc   28.10 %

Date modified: 2026-08-30T14:40:23+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.